High C-Terminal Fibroblast Growth Factor-23, Intact Parathyroid Hormone, and Interleukin-6 as Determinants of Valvular Calcification in Regular Hemodialysis Patients
Yenny Kandarini,Gede Wira Mahadita,Sianny Herawati,Ida Bagus Rangga Wibhuti,I Gde Raka Widiana,Nyoman Paramita Ayu
DOI: https://doi.org/10.2147/IJGM.S359168
IF: 2.145
2022-04-20
International Journal of General Medicine
Abstract:Yenny Kandarini, 1 Gede Wira Mahadita, 1 Sianny Herawati, 2 Ida Bagus Rangga Wibhuti, 3 I Gde Raka Widiana, 1 Nyoman Paramita Ayu 1 1 Department of Internal Medicine, Division of Nephrology and Hypertension, Udayana University Sanglah Hospital, Denpasar, Bali, Indonesia; 2 Department of Clinical Pathology and Laboratory Medicine, Udayana University Sanglah Hospital, Denpasar, Bali, Indonesia; 3 Department of Cardiology and Vascular Medicine, Udayana University Sanglah Hospital, Denpasar, Bali, Indonesia Correspondence: Yenny Kandarini, Department of Internal Medicine, Division of Nephrology and Hypertension, Udayana University Sanglah Hospital, P.B. Sudirman Street, Dangin Puri Klod, West Denpasar, Denpasar, 80234, Bali, Indonesia, Tel +628123803844 ; +62361 223797, Email Purpose: Biggest cause of death in chronic kidney disease-hemodialysis (CKD-HD) patients is cardiovascular disease (CVD). Cardiovascular disease is often associated with mineral bone disorders (MBD), especially vascular and valvular calcification. Biomarkers such as C-terminal-fibroblast growth factor-23 (FGF-23), intact parathyroid hormone (iPTH), and interleukin-6 (IL-6) were investigated. Only few studies have focused on valvular calcification in CKD-HD patients, with controversial results. The present study aimed to investigate whether high C-terminal-FGF-23, iPTH, and IL-6 can be used as determinants of valvular calcification in CKD-MBD patients undergoing regular HD. Patients and Methods: This was an analytical cross-sectional study which involved CKD-HD patients aged 18– 60 years with no history of CVD, malignancy, and diabetes mellitus. C-terminal FGF-23 was measured using enzyme-linked immunosorbent assay (ELISA) kit, iPTH using chemiluminescent immunometric method, and IL-6 using sandwich enzyme immunoassay technique. Valvular calcification on aortic and mitral valves was examined with echocardiography. Data analysis was done using Chi-squared test or Fisher's exact test as appropriate and multivariate logistic regression analysis. Results: Bivariate analysis with Fisher's exact test showed significant association of prevalence ratio (PR) of C-terminal FGF-23 (PR = 1.33; p = 0.003; CI (1.017– 1.748)), iPTH (PR = 1.361; p = 0.002; CI (1.02– 1.816)), and IL-6 (PR = 1.2; p = 0.019; CI (1.000– 1.446)) with valvular calcification. Multivariate analysis with logistic regression showed high C-terminal FGF-23 (exp (B) value of 16.44; p = 0.045; CI (1.07– 252.75)), iPTH (exp (B) value of 33.312; p = 0.016; CI (1.94– 571.71)), and IL-6 (exp (B) value of 21.58; p = 0.0381; CI (1.18– 394.87)) were determinants of valvular calcification in CKD-MBD patients undergoing regular HD. Conclusion: This study demonstrated that high C-terminal FGF-23, iPTH, and IL-6 were determinants of valvular calcification in CKD-MBD patients undergoing regular HD. Keywords: dialysis, end-stage renal disease, inflammation, hormone Chronic kidney disease (CKD) is a worldwide problem. It is estimated that 10% of the world's population suffer from it and the number keeps increasing especially in developing countries, including Indonesia. 1,2 In Indonesia, prevalence of CKD reached 3.8% in 2018, up from 1.8% in 2013. 3 This number is followed by increasing number of active renal replacement therapy (RRT) patients with hemodialysis (HD) still playing a primary role. In 2017, data from Indonesia Renal Registry (IRR) showed number of active patients undergoing HD reached 77,892 people. 4 High incidence of CKD and increasing number of RRT patients cause several problems, such as high financial burden and high mortality rate. In America, health cost burden of CKD keeps increasing from 41.2 billion US Dollars (USD) in 2010 to 50.4 billion USD in 2014. 1 In Indonesia, the average annual cost per patient was 7,845.6 USD with HD as the largest proportion of the cost (4,217.2 USD), followed by the cost of medicine (1,286.1 USD). 5 This shows CKD-HD is causing high financial burden to patients and health social security in the world. Msaad et al did a cohort study on CKD-HD patients and found high mortality rate in those patients. Cardiovascular disease (CVD), inflammation, and age were associated with CVD and all-cause mortality. 6 In 2017, highest cause of death in CKD-HD patients in Indonesia was CVD with mortality rate reaching 1,480 patients (37.3%). 4 Chronic complications of CKD that are often associated with CVD are mineral and bone disorders in CKD (CKD-MBD). Mineral bone disorder causes vascular and valvular calcification. Current evidence suggests that impaired mineral homeostasis, hormonal imbalance, and inflammation play a -Abstract Truncated-
medicine, general & internal